From the Division of Nuclear Medicine, Department of Radiology, Seoul St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Clin Nucl Med. 2022 Aug 1;47(8):e554-e556. doi: 10.1097/RLU.0000000000004197. Epub 2022 Apr 4.
The clinical value of 16α-18F-fluoro-17 β-estradiol (18F-FES) PET in breast cancer has been widely investigated because it can visualize estrogen receptor-expressing lesions. This relatively new radiotracer adds clinical values by characterization of metastasis in double primary cancer. It also has advantage in finding small brain lesions, which has no background brain activity. Here, we present 18F-FES PET findings of brain and leptomeningeal metastases in a patient with breast and lung malignancy.
16α-18F-氟-17β-雌二醇（18F-FES）PET 在乳腺癌中的临床价值已得到广泛研究，因为它可以可视化雌激素受体表达的病变。这种相对较新的示踪剂通过对双原发癌转移的特征描述增加了临床价值。它在发现无背景脑活动的小脑部病变方面也具有优势。在此，我们介绍了一名患有乳腺和肺部恶性肿瘤患者的脑和软脑膜转移的 18F-FES PET 发现。
